# News | Champions Oncology Canonical URL: https://biopharmsignal.com/news/CSBR/news-champions-oncology-349bd91b Ticker: CSBR Company: Champions Oncology Source: Champions Oncology Published: 2026-07-08 21:06 EST Original Source URL: https://blog.championsoncology.com/news ## Summary Recent Posts Hackensack, NJ – September 13, 2023 – Champions Oncology, Inc. (Nasdaq: CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmac... ## Article Body Recent Posts Hackensack, NJ – September 13 , 2023 – Champions Oncology, Inc. (Nasdaq: CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for its first quarter of fiscal 2024, ended July 31, 2023. First Quarter and Recent Highlights: First quarter revenue of $12.6 million, a decline of 9% Strong quarterly bookings Hosting Scientific Symposium in Boston, MA on September 26 th Read More → HACKENSACK, NJ – August 22, 8:30 AM - Champions Oncology, Inc. (Nasdaq: CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, kicks off its annual series of events by hosting a scientific symposium at the Museum of Science, in Boston, Massachusetts on September 26 th . This year’s event, titled “Uncovering Integrative Approaches for Oncology Drug Development” will focus on how the integrated use of clinically relevant patient-derived models, multi-omics analytics, and high-complexity phenotypical assays are impacting the entire drug development continuum across multiple therapeutic modalities. Read More → HACKENSACK, NJ – August 1, 8:45AM - Champions Oncology, Inc. (Nasdaq: CSBR), a leading global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions, today announced an agreement to adopt BioVolume's leading 3D imaging and thermal technology as their primary means of capturing efficacy results. Through this multi-year agreement Champions Oncology will incorporate BioVolume’s cutting-edge thermal and 3D imaging platform into its broad portfolio of in vivo preclinical offerings. In alignment with Champions' consistent focus on delivering the highest quality data and scientific excellence, the adoption of BioVolume technology will enable the achievement of greater accuracy, reduced variability, and the generation of reliable insights to advance oncology drug development programs across different therapeutic modalities. Read More → Hackensack, NJ – July 24, 2023 – Champions Oncology, Inc. (Nasdaq: CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for the fiscal year and fourth quarter ended April 30, 2023. Read More → Hackensack, NJ - April 17, 2023 – Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled research organization that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic (PPMO) integration, announced the launch of its therapeutic discovery and development platform into a wholly owned subsidiary named Corellia AI (Corellia). Corellia launches out of Champions Oncology with a team of world class scientists advancing a robust pipeline of therapeutic programs and a unique discovery and development platform. The company will continue to leverage Champions' superior PDX Molecular Atlas and its living bank of PDX models as central tools in its proprietary target and therapeutic discovery platform. Read More → ## Recent Company News - 2026-07-08 21:06 EST — [Champions Oncology Reports Quarterly Revenue of $13.1 Million](https://biopharmsignal.com/news/CSBR/champions-oncology-reports-quarterly-revenue-of-13-1-million-9f7e33ee) — Source: Champions Oncology - 2026-07-08 21:06 EST — [Champions Oncology Announces a Multi-Year Agreement & Strategic Collaboration with BioVolume to Transform Reproducibility in Preclinical Oncology Efficacy Studies](https://biopharmsignal.com/news/CSBR/champions-oncology-announces-a-multi-year-agreement-strategic-collaboration-with-c65d8149) — Source: Champions Oncology - 2026-07-08 21:06 EST — [Champions Oncology Announces Remarkable Lineup of Speakers at its Translational Oncology Symposium in Boston in September 2023](https://biopharmsignal.com/news/CSBR/champions-oncology-announces-remarkable-lineup-of-speakers-at-its-translational--c4916c08) — Source: Champions Oncology - 2026-07-08 21:06 EST — [News | Champions Oncology](https://biopharmsignal.com/news/CSBR/news-champions-oncology-349bd91b) — Source: Champions Oncology - 2026-07-08 21:06 EST — [Champions Oncology Reports Quarterly Revenue of $12.6 Million](https://biopharmsignal.com/news/CSBR/champions-oncology-reports-quarterly-revenue-of-12-6-million-484f1741) — Source: Champions Oncology ## Related News - 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47) - 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0) - 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f) - 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c) - 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)